SGOC & SGO Select 2026 - Scientific Program & Master Agenda

SGO Select™ Official Program

Saudi Gynecology Oncology Congress 2026

SGO Select™ 2026 • Scientific Program & Master Agenda

View Schedule

Location Crowne Plaza RDC, Riyadh, Saudi Arabia

Event Dates 25–26 September 2026

Day I Master Schedule

Friday, September 25, 2026

Endometrial Cancer, Surgeries & Rare Tumors

Abstract Session

Session I: SGO - Endometrial Abstracts

Panel: Dr. Muneera Almajed, Dr. Hamza Ajaj, Dr. Hani Alhalal, Dr. Ibrahim Madkhali, Dr. Saad Alqarni

8:00 – 8:10

10 min

POLE mutation analysis, molecular characterization, and associations with survival outcomes: Ancillary analysis of GOG-0258

Dr. Walaa Al Jarie

8:10 – 8:20

10 min

HER2 overexpression does not impact survival in patients with stage I uterine serous carcinoma

Dr. Wafa AlDuwaisan

8:20 – 8:30

10 min

GOG-3039: A Phase II Trial of Abemaciclib Plus Letrozole in Recurrent or Persistent Endometrioid Endometrial Carcinoma (NCT04393285)

Dr. Tareq Hassan

8:30 – 8:40

10 min

Prediction of Response to Fertility Preserving Progestin Therapy for Endometrial Cancer Based on Molecular Subtype

Dr. Mohammed Alruwaisan

8:40 – 8:50

10 min

Adjuvant dostarlimab with pelvic radiation (RT) in locally advanced, mismatch repair-deficient (MMR-D) endometrial cancer (EC): D-RT Study

Prof. Ahmed Badheeb

8:50 – 9:00

10 min

Discussion

All

Keynote & Debate

Session II: Early Endometrial Cancer

Panel: Dr. Nashmia Almutairi, Dr. Khalid Alwadi, Dr. Hanan Mal, Dr. Sajid Durrani, Dr. Hatim Aldabbagh

9:00 – 9:30

30 min

Keynote Lecture

How Much Surgery Is Enough in the Molecular Era?

Dr. Giuseppe Caruso

9:30 – 10:00

30 min

DEBATE SESSION

FIGO Stage II & III EC (Radiation vs Immune + Chemo – KN-B21)

• 9:30–9:45: In favor of radiation (Dr. Nuha Jastaniah)

• 9:45–10:00: In favor of KN-B21 (Prof. Mansour Mirza)

Morning Break

10:00 – 10:15 (15 min)

10:15 – 10:45

30 min

Tumor Board I

Adjuvant Therapy Stage I-III EC (Sequential vs PORTEC vs GOG-258)

Presenters / Panel: Prof. Rania Chehade, Dr. Raul Marquez, Prof. Robert Coleman, Dr. Bassam Basulaiman, Dr. Abdulaziz Babair, Dr. Ahmad Nazer, Dr. Nuha Jastaniah, Dr. Mohamed Aseafan

10:45 – 11:15

30 min

SATELLITE: GSK Satellite

Immunotherapy in Endometrial Cancer, Evidence, Experience and Evolving Standards

Speaker: Dr. Mohammed Aseafan | Chair: Dr. Bassam Basulaiman

Opening Ceremony

11:15 – 11:30 (15 min)

Prayer & Lunch Break

11:30 – 13:00 (90 min)

Surgical Session

Session III: Role of Surgery in Endometrial Cancer

Panel: Dr. Ismail Al-Badawi, Dr. Ali Bassi, Dr. Amal Alsomari, Dr. Zyiad AlYami

13:00 – 13:20

20 min

Lecture: Vascular Complications in Minimally Invasive and Robotic Surgery

Dr. Vito Chiantera

13:20 – 13:40

20 min

Lecture: Advanced & Salvage Surgery in the IO Era

Dr. Anna Fagotti

13:40 – 13:50

10 min

Discussion

All

13:50 – 14:10

20 min

SATELLITE: AstraZeneca Satellite

AstraZeneca Satellite Symposium

Speaker: Prof. Robert Coleman | Moderator: Dr. Abdulrahman Alghabban

Afternoon Break

14:10 – 14:20 (10 min)

Debate & Advanced Care

Session IV: Advanced Endometrial Cancer Management

Panel: Dr. Wala Mehros, Dr. Abdulrahman Alghabban, Dr. Waleed Alselwi, Dr. Abdulaziz Asseri, Dr. Reem Alomran, Dr. Hani Salem

14:20 – 14:50

30 min

DEBATE SESSION

IO + Chemo vs IO + PARPi in Advanced MMRP EC

• 14:20–14:35: In favor of IO + chemo (Dr. Raul Marquez)

• 14:35–14:50: In favor of IO + PARPI (Prof. Robert Coleman)

14:50 – 15:10

20 min

Lecture: Best Sequence After IO + Chemo & Future Directions

Dr. Raul Marquez

15:10 – 15:20

10 min

Discussion

All

15:20 – 15:50

30 min

SATELLITE: MSD Satellite

MSD Satellite Symposium

Speaker: Prof. Robert Coleman

15:50 – 16:10

20 min

SATELLITE: Eisai Satellite

Eisai Satellite Symposium

Speaker: Dr. Abdulrahman Algabban | Chair: Dr. Abdulraheem Alshangiti

Specialty Care

Session V: Rare Tumor

Panel: Dr. Mustafa Almubarak, Dr. Khalid Alkhalifa, Fouad Alnajjar, Dr. Ibrahim Al Sharaydeh, Dr. Khalid Bawazir

16:10 – 16:25

15 min

Lecture: Uterine Sarcoma in 2026

Dr. Alejandro Gallego

16:25 – 16:40

15 min

Lecture: Low-Grade Serous Ovarian Cancer: Any update

Prof. Rania Chehade

16:40 – 16:55

15 min

New management strategies for WHO scores 5-6 and high risk GTN

Prof. Robert Coleman

16:55 – 17:05

10 min

Discussion

All

Day 1 Closing

17:05

Day II Master Schedule

Saturday, September 26, 2026

Ovarian Abstracts, Surgery & Cervix Updates

Abstract & Satellite Session

Session I: SGO - Ovarian Abstracts

8:00 – 8:10

10 min

Results of a Randomized Phase III Trial of Letrozole Alone Versus Paclitaxel and Carboplatin Followed by Letrozole as Initial Treatment for Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Low-Grade Serous Carcinoma (NRG-GY019, NCT04095364)

Dr. Faisal Azam

8:10 – 8:20

10 min

Mirvetuximab soravtansine plus carboplatin in folate receptor alpha-expressing recurrent platinum-sensitive ovarian cancer

Dr. Duaa Binjabal

8:20 – 8:30

10 min

Impact of intraoperative capsule rupture on survival in early-stage clear cell ovarian carcinoma

Dr. Mazin Baazeem

8:30 – 8:40

10 min

Final Overall Survival (OS) Results From the Phase 3 ROSELLA Trial: Relacorilant Plus Nab-Paclitaxel vs Nab-Paclitaxel Monotherapy in Patients With Platinum-Resistant Ovarian Cancer (PROC)

Dr. Hassan Sabbagh

8:40 – 8:50

10 min

Utilization and outcomes of fertility-sparing ovarian cystectomy for stage I malignant ovarian germ cell tumors

Dr. Ali Alhanash

8:50 – 9:00

10 min

Discussion

All

9:00 – 9:20

20 min

SATELLITE: GSK

Redefining the Treatment Paradigm in Advanced Ovarian Cancer

Speaker: Dr. Tariq Salah | Moderator: Dr. Abdulrahman Alghabban

Surgical Care

Session II: Surgery in Ovarian Tumors

Panel: Prof. Khalid Sait, Prof. Maria Arafah, Dr. Abdulraheem Alshangiti, Dr. Thamer AlGhamdi, Dr. Rami Khalifa, Dr. Mohammad Alyafi, Dr. Nora Alibrahim, Dr. Basel Refky, Dr. Eman Alshehri, Dr. Khalid Alwadi

9:00 – 9:20

20 min

How Can We Select Patients for Primary Surgery or Neoadjuvant Chemotherapy in Ovarian Cancer?

Dr. Anna Fagotti

9:20 – 9:40

20 min

Fertility Preservation in Borderline Ovarian Cancer: Surgical Indications and Limits

Dr. Philippe Morice

9:40 – 10:00

20 min

Lessons Learned from Complications in Cytoreductive Surgery

Dr. Mustafa Muallem

10:00 – 10:10

10 min

Discussion

10:10 – 10:30

20 min

SATELLITE: AstraZeneca

HER2 in Gyne Cancers: An Emerging Therapeutic Paradigm

Moderator: Dr. Bassam Basulaiman

Molecular Therapeutics

Session III: Molecular Guided Therapies in Ovarian Cancer

Panel: Dr. Hamed Alhussaini, Dr. Abdulmohsen Alkushi, Dr. Mohamed Alhassan, Dr. Najwa Buhlaiga

10:30 – 10:50

20 min

Targeting Molecular Pathways in Gynecologic Cancers

Dr. Abbas Agaimy

10:50 – 11:10

20 min

Rechallenge with PARP-I and options of maintenance in platinum sensitive EOC

Dr. Shibani Nicum

11:10 – 11:25

15 min

Lecture: The emerging role of ADCs in platinum sensitive ovarian cancer

Prof. Susana Banerjee

11:25 – 11:45

20 min

Evolving Treatment Paradigms in Platinum-Resistant Ovarian Cancer

Prof. Mansour Mirza

11:45 – 11:55

10 min

Discussion

Prayer & Lunch Break

11:55 – 12:55 (60 min)

12:55 – 13:55

60 min

SATELLITE

Abbvie Satellite Symposium

Mid-Afternoon Break

13:55 – 14:05 (10 min)

Cervix Oncology & Parallel Room

Session IV: SGO - Cervix Cancer

Panel: Dr. Rayyan Hasanain, Dr. Mohammad Aboziada, Dr. Osama Alomar, Dr. Yasmin Al-Saqiah, Dr. Abdullah Basahieh

14:05 – 14:15

10 min

Pathologic response to hypofractionation in locally advanced cervical cancer

Dr. Saad Alrashidi

14:05 – 15:05

60 min

PARALLEL ROOM WORKSHOP

AstraZeneca Workshop: HER2 in Practice: From Testing to Treatment

Speakers: Dr. Mohamed Aseafan, Dr. Abdulmohsen Alkushi, Dr. Alejandro Gallego

Panel: Dr. Nashmia Almutairi, Dr. Mohammad Alyafi, Dr. Abdulrahman Alghabban, Dr. Waleed Alselwi

14:15 – 14:25

10 min

Sacituzumab Tirumotecan (Sac-TMT) Plus Pembrolizumab in Participants With Recurrent or Metastatic Cervical Cancer: Results From Phase 2 2870-002/SKB264-11-06 Study

Dr. Sharif Kulab

14:25 – 14:35

10 min

Beyond Sedlis: Validation of histology-specific risk factors for stage I cervical squamous cell carcinoma and adenocarcinoma

Dr. Tawfeeq Tawfeeq

14:35 – 14:45

10 min

Discussion

All

14:45 – 15:15

30 min

SATELLITE

MSD Satellite Symposium

Debate & Updates

Session V: Updates in Cervix Cancer

Panel: Dr. Om Alkhair Abu Alkhair, Dr. Khalid Akkour, Dr. Faiz Alshafa, Dr. Hashem Al Hashem

15:15 – 15:35

20 min

Surgery in Bulky / Locally Advanced Cervical Cancer: Quality & Performance Metrics

Dr. Mustafa Muallem

15:35 – 15:55

20 min

Beyond First-Line Treatment in Advanced Cervical Cancer

Prof. Mansour Mirza

15:55 – 16:15

20 min

DEBATE SESSION

INTERLACE vs Keynote-A18 in FIGO Stage IIB Cervix Cancer

• 15:55–16:05: In favor of INTERLACE (Dr. Anes Pasic)

• 16:05–16:15: In favor of Keynote-A18 (Dr. Alejandro Gallego)

16:15 – 16:35

20 min

Role of Re-irradiation in Central Recurrence of Cervical Cancer

Dr. Yasir Alayed

16:35 – 17:05

30 min

PARALLEL ROOM FORUM

Saudi Canadian Collaboration Forum

16:35 – 16:50

15 min

SATELLITE: Glenmark Satellite

Glenmark Satellite Symposium

Speaker: Prof. Shawqi Bazarbashi | Moderator: Dr. Mohamed Aseafan

Closing Remarks

16:50 – 16:55 (5 min)

Friday, September 25, 2026

Session I: SGO - Endometrial Abstracts

POLE mutation analysis, molecular characterization, and associations with survival outcomes: Ancillary analysis of GOG-0258

HER2 overexpression does not impact survival in patients with stage I uterine serous carcinoma

GOG-3039: A Phase II Trial of Abemaciclib Plus Letrozole in Recurrent or Persistent Endometrioid Endometrial Carcinoma (NCT04393285)

Prediction of Response to Fertility Preserving Progestin Therapy for Endometrial Cancer Based on Molecular Subtype

Adjuvant dostarlimab with pelvic radiation (RT) in locally advanced, mismatch repair-deficient (MMR-D) endometrial cancer (EC): D-RT Study

Discussion

Session II: Early Endometrial Cancer

How Much Surgery Is Enough in the Molecular Era?

FIGO Stage II & III EC (Radiation vs Immune + Chemo – KN-B21)

Adjuvant Therapy Stage I-III EC (Sequential vs PORTEC vs GOG-258)

Immunotherapy in Endometrial Cancer, Evidence, Experience and Evolving Standards

Session III: Role of Surgery in Endometrial Cancer

Lecture: Vascular Complications in Minimally Invasive and Robotic Surgery

Lecture: Advanced & Salvage Surgery in the IO Era

Discussion

AstraZeneca Satellite Symposium

Session IV: Advanced Endometrial Cancer Management

IO + Chemo vs IO + PARPi in Advanced MMRP EC

Lecture: Best Sequence After IO + Chemo & Future Directions

Discussion

MSD Satellite Symposium

Eisai Satellite Symposium

Session V: Rare Tumor

Lecture: Uterine Sarcoma in 2026

Lecture: Low-Grade Serous Ovarian Cancer: Any update

New management strategies for WHO scores 5-6 and high risk GTN

Discussion

Saturday, September 26, 2026

Session I: SGO - Ovarian Abstracts

Results of a Randomized Phase III Trial of Letrozole Alone Versus Paclitaxel and Carboplatin Followed by Letrozole as Initial Treatment for Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Low-Grade Serous Carcinoma (NRG-GY019, NCT04095364)

Mirvetuximab soravtansine plus carboplatin in folate receptor alpha-expressing recurrent platinum-sensitive ovarian cancer

Impact of intraoperative capsule rupture on survival in early-stage clear cell ovarian carcinoma

Final Overall Survival (OS) Results From the Phase 3 ROSELLA Trial: Relacorilant Plus Nab-Paclitaxel vs Nab-Paclitaxel Monotherapy in Patients With Platinum-Resistant Ovarian Cancer (PROC)

Utilization and outcomes of fertility-sparing ovarian cystectomy for stage I malignant ovarian germ cell tumors

Discussion

Redefining the Treatment Paradigm in Advanced Ovarian Cancer

Session II: Surgery in Ovarian Tumors

How Can We Select Patients for Primary Surgery or Neoadjuvant Chemotherapy in Ovarian Cancer?

Fertility Preservation in Borderline Ovarian Cancer: Surgical Indications and Limits

Lessons Learned from Complications in Cytoreductive Surgery

Discussion

HER2 in Gyne Cancers: An Emerging Therapeutic Paradigm

Session III: Molecular Guided Therapies in Ovarian Cancer

Targeting Molecular Pathways in Gynecologic Cancers

Rechallenge with PARP-I and options of maintenance in platinum sensitive EOC

Lecture: The emerging role of ADCs in platinum sensitive ovarian cancer

Evolving Treatment Paradigms in Platinum-Resistant Ovarian Cancer

Discussion

Abbvie Satellite Symposium

Session IV: SGO - Cervix Cancer

Pathologic response to hypofractionation in locally advanced cervical cancer

AstraZeneca Workshop: HER2 in Practice: From Testing to Treatment

Sacituzumab Tirumotecan (Sac-TMT) Plus Pembrolizumab in Participants With Recurrent or Metastatic Cervical Cancer: Results From Phase 2 2870-002/SKB264-11-06 Study

Beyond Sedlis: Validation of histology-specific risk factors for stage I cervical squamous cell carcinoma and adenocarcinoma

Discussion

MSD Satellite Symposium

Session V: Updates in Cervix Cancer

Surgery in Bulky / Locally Advanced Cervical Cancer: Quality & Performance Metrics

Beyond First-Line Treatment in Advanced Cervical Cancer

INTERLACE vs Keynote-A18 in FIGO Stage IIB Cervix Cancer

Role of Re-irradiation in Central Recurrence of Cervical Cancer

Saudi Canadian Collaboration Forum

Glenmark Satellite Symposium

About SGOC 2026

Useful Links

Congress Location

© 2026 SGOC . All Rights Reserved